MGEN vs. ENZ, PSNL, XGN, DMTK, PMD, BDSX, ICCM, SRTS, RPHM, and AMIX
Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Enzo Biochem (ENZ), Personalis (PSNL), Exagen (XGN), DermTech (DMTK), Psychemedics (PMD), Biodesix (BDSX), IceCure Medical (ICCM), Sensus Healthcare (SRTS), Reneo Pharmaceuticals (RPHM), and Autonomix Medical (AMIX). These companies are all part of the "medical" sector.
Enzo Biochem (NYSE:ENZ) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, community ranking, institutional ownership and media sentiment.
36.9% of Enzo Biochem shares are owned by institutional investors. 15.5% of Enzo Biochem shares are owned by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Enzo Biochem has higher revenue and earnings than Miragen Therapeutics.
Miragen Therapeutics received 55 more outperform votes than Enzo Biochem when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Enzo Biochem has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
In the previous week, Enzo Biochem had 2 more articles in the media than Miragen Therapeutics. MarketBeat recorded 2 mentions for Enzo Biochem and 0 mentions for Miragen Therapeutics. Miragen Therapeutics' average media sentiment score of 0.24 beat Enzo Biochem's score of 0.00 indicating that Enzo Biochem is being referred to more favorably in the media.
Enzo Biochem has a net margin of 99.28% compared to Enzo Biochem's net margin of -1,393.50%. Miragen Therapeutics' return on equity of -36.71% beat Enzo Biochem's return on equity.
Summary
Enzo Biochem beats Miragen Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Miragen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Miragen Therapeutics Competitors List
Related Companies and Tools
